News April 2017

On April 10, 2017 Enzyre obtained an exclusive license of the Radboudumc to a proprietary technology using chemiluminescence to detect enzymatic reactions using a light sensor chip and enzyme specific substrates. The technology was developed with funding of a PIDON grant by a consortium including NXP Semiconductors and Chiralix. The license agreement includes the option to purchase the patent protecting the technology. Enzyre will use the technology to develop a point-of-care biochip for blood coagulation able to measure multiple enzymatic reaction simultaneously. Together with the execution of the license agreement Radboudumc became a shareholder in Enzyre and invested an undisclosed amount in the development of the biochip.

Company
  • Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.
Enzyre BV
  • Transistorweg 5
  • 6534-AT Nijmegen
  • The Netherlands
  • Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.
Follow us